Genmab and AbbVie Report P-I/II Trial (EPCORE NHL-1) Results of Epcoritamab for the Treatment of Relapsed/Refractory Follicular Lymphoma
Shots:
- The P-I/II trial (EPCORE NHL-1) consists of three parts i.e., a P-I first-in-human, dose escalation part; a P-II expansion part, and an optimization part evaluating epcoritamab in adult patients with r/r FL. Epcoritamab is being co-developed by Genmab and AbbVie
- The results showed an ORR (82%) as confirmed by IRC which exceeded the protocol prespecified threshold for efficacy, m-DoR was not reached & no new safety signals were observed, cytokine release syndrome (66.4%)
- The company will discuss the results with global regulatory authorities to discuss the next steps. Epcoritamab, an investigational IgG1-bispecific Ab that was developed using Genmab's DuoBody technology
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie and Genmab's Epkinly (epcoritamab-bysp) Receives the US FDA’s Approval for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
